Home » Newsletters » BioWorld Science

BioWorld Science

April 11, 2019

View Archived Issues

Diversion is novel way of enzyme inhibition

Potassium promotes T-cell stemness

New model to trial schizophrenia preventative treatments

FDA accepts IND application for first-in-human study of PSB-205

Galapagos initiates first-in-human trial of GLPG-3121

U.S. researchers present a 5-HT2A receptor inhibitor antibody

Merck & Co. identifies new nicotinic alpha-7 receptor positive allosteric modulators

CCDC102B is strongly correlated with negative clinical outcome in breast cancer

Menin/MLL interaction inhibitors discovered at Kura Oncology

Kymera Therapeutics discovers protein cereblon inhibitors

ESSA Pharmaceuticals presents the characterization of next-generation Anitens

Leo Pharma patents phosphodiesterase PDE4D inhibitors

ABM Therapeutics presents V600E mutant raf kinase B inhibitors

Phase Ib/II data presented for DV-281 in combination with nivolumab in patients with NSCLC

New and potent IDO1 inhibitors from Merck & Co. presented

I-Mab Biopharma collaborates with Roche on clinical study of TJD-5 with Tecentriq

Alkeus begins phase III study of ALK-001 for GA secondary to AMD

Sanaria announces agreements to support development of PfSPZ vaccine for malaria

AstraZeneca DNA-PK inhibitor AZD-7648 has single-agent and combination antitumor activity

New phase I trial evaluates AVID-200 in patients with myelofibrosis

Evotec and Indivumed to use IndivuType database for colorectal cancer drug discovery

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...